Mira Pharmaceuticals (MIRA) said Thursday it has expanded its pain management portfolio by developing topical formulation of Ketamir-2 to treat localized neuropathic and inflammatory pain.
The topical treatment of Ketamir-2 is developed for "slow release" to directly target the pain site, while also reducing systemic exposure and side effects, the company said, adding that potential applications include neuropathic pain conditions, inflammatory pain conditions, and nerve compression & musculoskeletal pain.
Mira said it is currently carrying out a phase 1 clinical study for the Ketamir-2 oral treatment for neuropathic pain.
MIRA shares were 3% higher ahead of Thursday's opening bell.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。